Eluvia banner image

A New Standard Of Care In SFA Stenting

Eluvia Drug-Eluting Stent

Eluvia™️drug-eluting stent consistently outperforms other SFA stents - no matter the lesion complexity, no matter the patient

Eluvia™ consistently outperforms other SFA stents – no matter the lesion complexity, no matter the patient

Restenosis poses a significant, prevalent challenge in superior femoral artery (SFA) disease  management. Boston Scientific is dedicated to overcoming peripheral arterial disease (PAD) challenges with bold innovation using next-generation drug-eluting technology. Eluvia is built for sustained drug release and efficient drug transfer. Regardless of patient or lesion complexity, Eluvia has durable and consistent results in two level-1 comparative effectiveness trials.

Icon representing positive result

Superior primary 
patency over bare metal stents
(BMS) and Zilver™ paclitaxel (PTX)1,2

Icon representing trial outcomes

~90% in complex lesions in both RCT and real world data3,4

Icon representing reduction

Low revascularisation 
rate of 70.7% at 5 years5 in the IMPERIAL RCT data presented at CRT 2023

EMINENT clinical trial
IMPERIAL clinical trial

Eluvia demonstrated superior primary patency over BMS (EMINENT) and Zilver PTX (IMPERIAL)¹⁻²

Eluvia patency versus Zilver/BMS
EMINENT clinical trial
IMPERIAL clinical trial

Primary patency ~90% in complex lesions in both RCT and RWE at 1 year³⁻⁴

RWE versus RCT patency

7 out of every 10 Eluvia patients did not require a reintervention within 5 years

Eluvia low revascularization rate

Low revascularisation rate of 70.7% at 5 years⁵

Eluvia demonstrated a similar mortality rate versus the expected range for symptomatic PAD patients at 5 years⁵⁻⁶

Eluvia mortality versus PAD
Icon representing download resources

Receive downloads for clinical data sheets and additional resources for our Drug-Eluting Technologies.

Explore resources
Icon representing get updates

Stay up to date with the latest DET news and events in your area.
 

Register

References

  1. Gouëffic Y, et al. Efficacy of a drug-eluting stent versus bare metal stents for symptomatic femoropopliteal peripheral artery disease: Primary results of the EMINENT randomized trial. Circulation. 2022;146:1564–1576.
  2. Müller-Hülsbeck S, et al. Two-year efficacy and safety results from the IMPERIAL Randomized study of the Eluvia polymer-coated drug-eluting stent and the Zilver PTX polymer-free drug-coated stent. Cardiovasc Intervent Radiol. 2021;44:368–375.
  3. Lida O, et al. 1-year outcomes of fluoropolymer-based drug-eluting stent in femoropopliteal practice: predictors of restenosis and aneurysmal degeneration. JACC Cardiovasc Interv. 2022;15:630–638.
  4. Golzar, J. et al, Effectiveness and safety of a paclitaxel-eluting stent for superficial femoral artery lesions up to 190 mm: one-year outcomes of the single-arm IMPERIAL long lesion substudy of the Eluvia drug-eluting stent. J Endovasc Ther. 2020;27:296–303.
  5. Gray W, et al. CRT-300.01 Five-Year Results From the IMPERIAL Randomized Study of Eluvia and Zilver PTX Drug-Eluting Stents and the Long Lesion Sub-Study for Femoropopliteal Artery Disease. J Am Coll Cardiol Intv. 2023;16(4):S55.
  6. Sartipy, F. Ten Year Mortality in Different Peripheral Arterial Disease Stages: A Population Based Observational Study on Outcome. Eur J Vasc Endovasc Surg. 2018;55(4):529–536.

Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.